Dimerix Bioscience Pty Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Dimerix Bioscience Pty Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013101
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dimerix Bioscience Pty Ltd (Dimerix), a subsidiary of Sun Biomedical Ltd is a biopharmaceutical company that offers drug discovery assays and progressing clinical programs. The company provides product development, discovery services, and others. It provides Receptor-HIT a cell-based assay applied to the stages of the drug development process. Dimerix’s heteromer identification technology assay is an assay configuration that enables readout of heteromer specific signalling triggered by ligands. The company’s assay is used across G protein coupled receptors and associated signalling pathways. It offers products for receptors screening and profiling applications, and to interrogate multiple different signalling pathways and protein interactions. The company operates through laboratories in Nedlands, Western Australia; and operates in the US, Australia and Europe. Dimerix is headquartered in Melbourne, Victoria, Australia.

Dimerix Bioscience Pty Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Dimerix Bioscience Pty Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Dimerix Bioscience Pty Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Dimerix Bioscience Pty Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Dimerix Bioscience Pty Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Dimerix Bioscience Pty Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Dimerix Bioscience Pty Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Dimerix Enters Into Second Research Agreement With Takeda Cambridge 10
Equity Offering 11
Dimerix Bioscience Withdraws IPO for USD8.4 Million 11
Acquisition 12
Sun Biomedical Acquires Dimerix Bioscience 12
Dimerix Bioscience Pty Ltd – Key Competitors 14
Dimerix Bioscience Pty Ltd – Key Employees 15
Dimerix Bioscience Pty Ltd – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Product Approvals 17
Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA 17
Clinical Trials 19
Dec 06, 2016: Dimerix Completes Recruitment of Part A of its Phase 2 Trial of DMX-200 in Chronic Kidney Disease 19
Oct 04, 2016: Interim analysis supports continued development of DMX – 200 for the treatment of Chronic Kidney Disease 20
Jul 27, 2016: Dimerix Announces Pre-clinical Program, DMX-250, Targeting Heterodimers active in NASH, a major Liver Disease 21
Jun 06, 2016: Dimerix reaches 10 patient milestone and on Track to Report Interim Phase II Trial Data of DMX-200 in Patients with Chronic Kidney Disease in Q3 2016 22
Feb 19, 2016: Dimerix receives US Patent allowance for chronic kidney disease drug candidate 23
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Dimerix Bioscience Pty Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Dimerix Bioscience Pty Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Dimerix Bioscience Pty Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Dimerix Bioscience Pty Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Dimerix Bioscience Pty Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Dimerix Bioscience Pty Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Dimerix Enters Into Second Research Agreement With Takeda Cambridge 10
Dimerix Bioscience Withdraws IPO for USD8.4 Million 11
Sun Biomedical Acquires Dimerix Bioscience 12
Dimerix Bioscience Pty Ltd, Key Competitors 14
Dimerix Bioscience Pty Ltd, Key Employees 15
Dimerix Bioscience Pty Ltd, Other Locations 16

★海外企業調査レポート[Dimerix Bioscience Pty Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Finning International Inc (FTT):企業の財務・戦略的SWOT分析
    Finning International Inc (FTT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Tata Global Beverages Limited:企業の戦略・SWOT・財務情報
    Tata Global Beverages Limited - Strategy, SWOT and Corporate Finance Report Summary Tata Global Beverages Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Eris Lifesciences Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Eris Lifesciences Ltd (Eris Lifesciences) is a pharmaceutical company that manufactures and commercializes generics products. The company through its divisions provides wide range of products including Maxum, Decal, Eritel H, Eritel CH 80 LS, Glimisave Max Forte 1, Mac Rabonik Plus, Vomisave …
  • Verbundnetz Gas Aktiengesellschaft-石油・ガス分野:企業M&A・提携分析
    Summary Verbundnetz Gas Aktiengesellschaft (VNG), a subsidiary of EnBW Energie Baden-Wurttemberg AG, is a natural gas company that explores, produces, stores, trades and transports natural gas. The company has natural gas licenses on the Norwegian continental shelf and the Danish Central Graben regi …
  • PT Kimia Farma (Persero) Tbk (KAEF):製薬・医療:M&Aディール及び事業提携情報
    Summary PT Kimia Farma (Persero) Tbk (Kimia Farma) manufactures, commercializes and distributes pharmaceutical products. The company provides ethical (prescription), generic and other products. It offers products in various categories including alimentary system, allergy and immune system, system an …
  • Ulster Bank Ireland DAC:企業の戦略的SWOT分析
    Ulster Bank Ireland DAC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Bank Hapoalim BM:企業の戦略・SWOT・財務情報
    Bank Hapoalim BM - Strategy, SWOT and Corporate Finance Report Summary Bank Hapoalim BM - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft:企業の戦略・SWOT・財務情報
    Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft - Strategy, SWOT and Corporate Finance Report Summary Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers th …
  • Reply SpA (REY):企業の財務・戦略的SWOT分析
    Reply SpA (REY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Nidec Corporation:企業の戦略・SWOT・財務分析
    Nidec Corporation - Strategy, SWOT and Corporate Finance Report Summary Nidec Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Tillotts Pharma AG-製薬・医療分野:企業M&A・提携分析
    Summary Tillotts Pharma AG (Tillotts), a subsidiary of Zeria Pharmaceutical Co Ltd is a healthcare solution provider that develops, licenses and markets pharmaceutical products, medical devices and diagnostics in the field of gastroenterology. The company’s products are used for the treatment of var …
  • Colorado State University-製薬・医療分野:企業M&A・提携分析
    Summary Colorado State University (CSU) is a public research university that offers various academic programs. It provides graduate degree programs, undergraduate degree programs, research programs, summer programs and honor programs. Its schools and programs include graduate school, international p …
  • IntegraGen SA (ALINT):製薬・医療:M&Aディール及び事業提携情報
    Summary IntegraGen SA (IntegraGen) is a developer and commercializer of molecular diagnostic tests for the treatment of autism and oncology. The company provides advanced genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis …
  • United BioSource Corp-製薬・医療分野:企業M&A・提携分析
    Summary United BioSource Corp (UBC), a subsidiary of Express Scripts Holding Company is a provider of pharmaceutical support services. The company offers medicines and medical products. Its services comprise clinical development and late stage research, risk management and pharmacovigilance, nursing …
  • PAREXEL International Corporation:企業の戦略・SWOT・財務分析
    PAREXEL International Corporation - Strategy, SWOT and Corporate Finance Report Summary PAREXEL International Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Total SA (FP):企業の財務・戦略的SWOT分析
    Total SA (FP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Paradigm Biopharmaceuticals Ltd (PAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Paradigm Biopharmaceuticals Ltd (Paradigm Biopharma) is a biopharmaceutical company. The company focused on research and development of therapeutic products for human use. It offers pentosan polysulphate sodium (PPS) drugs for new orthopaedic and respiratory applications. Paradigm Biopharma …
  • The Nassau Companies of New York:企業の戦略的SWOT分析
    The Nassau Companies of New York - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Kareo Inc:医療機器:M&Aディール及び事業提携情報
    Summary Kareo Inc (Kareo) provides a cloud-based medical technology platform that meets the needs of healthcare providers. The company offers cloud-based electronic health records (EHR) that helps clinicians to manage the care of the patients and record or access required information at the point of …
  • Shield Therapeutics Plc (STX):企業の財務・戦略的SWOT分析
    Summary Shield Therapeutics Plc (Shield Therapeutics) is a specialty pharmaceutical company that focus on the development and commercialization products for the treatment of anaemia associated with renal and gastrointestinal disorders. The company’s product portfolio includes Feraccru, a stable, non …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆